IP Library Granted Patent US 7,060,020
Granted Patent B2
US 7,060,020 · App. 10/035,083 · Granted Jun 13, 2006

Delivery system and method for interstitial radiation therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,060,020
App. No.
10/035,083
Granted
Jun 13, 2006
Kind
B2
Abstract

A delivery system and method for interstitial radiation therapy comprising a substantially axially stiff and longitudinally flexible elongated member made of material, which is bio-absorbable in living tissue and a plurality of radioactive seeds dispersed in a predetermined array within the member. The delivery system and method further customize the member based on a prescription.

Claims (72)

1. A therapeutic element comprising:

a polymeric material;

a plurality of radioactive seed elements; wherein

said polymeric material forms an elongated member by encapsulating and connecting adjacent radioactive seed elements end-to-end at desired intervals; and

said elongated member being axially rigid and radially flexible.

2. The therapeutic element of claim 1 wherein the polymeric material is a polymer.

3. The therapeutic element of claim 1 wherein the polymeric material is a co-polymer.

4. The therapeutic element of claim 1 wherein the polymeric material is a natural bio-compatible material.

5. The therapeutic element of claim 1 wherein the polymeric material is a synthetic bio-compatible material.

6. The therapeutic element of claim 1 wherein the polymeric material is a natural bio-absorbable material.

7. The therapeutic element of claim 1 wherein the polymeric material is a synthetic bio-absorbable material.

8. The therapeutic element of claim 1 wherein the elongated member has alternating segments of polymeric material and seed elements.

9. The therapeutic element of claim 1 wherein the elongated member has a substantially constant diameter.

10. The therapeutic element of claim 1 wherein the elongated member has a diameter substantially similar to the diameter of the radioactive seed elements.

11. The therapeutic element set forth in claim 1 wherein said elongate member is sufficiently rigid axially to prevent jamming or collapsing while being pushed out of a needle.

12. The therapeutic element set forth in claim 1 wherein said elongate solid member has sufficient radial flexibility to maintain locational accuracy relative to a tumor target as said tumor target shrinks in size.

13. The therapeutic element set forth in claim 1 wherein the thickness of said elongate solid member around said radioactive seeds is sufficient to decrease normal tissue necrosis from a high local dose of radiation.

14. The therapeutic element set forth in claim 1 wherein said elongate solid member is longitudinally flexible.

15. The therapeutic element set forth in claim 1 wherein said polymeric material is impregnated with a hormone.

16. The therapeutic element set forth in claim 1 wherein said polymeric material is impregnated with a drug.

17. The therapeutic element set forth in claim 1 wherein said radioactive seed elements are positioned at various intervals along the length of said elongate solid member.

18. The therapeutic element set forth in claim 1 wherein said radioactive seed elements are impregnated with a hormone.

19. The therapeutic element set forth in claim 1 wherein said radioactive seed elements are impregnated with a drug.

20. The therapeutic element set forth in claim 1 wherein said radioactive seeds contain a compound or element that emits photonic radiation having a low energy and a short half-life.

21. The therapeutic element set forth in claim 1 wherein said radioactive seeds contain an isotope consisting of the group iodine 125, palladium 103, iridium 192, cesium 131, gold 198 yttrium 90 and phosphorus 32.

22. The therapeutic element set forth in claim 1 wherein said polymeric material is absorbed by living tissue within about 70 to 120 days after implant.

23. The therapeutic element set forth in claim 1 wherein said polymeric material is absorbed by living tissue at substantially the same time as the half-life of the radioactive seed elements are reached.

24. The therapeutic element set forth in claim 1 wherein said polymeric material is selected from the group consisting of polymers and copolymers of glycolide, lactide and polydiaxanone.

25. The therapeutic element set forth in claim 1 wherein said elongate solid member is echogenic.

26. The therapeutic element set forth in claim 1 wherein said elongate solid member has air bubbles dispensed within.

27. The therapeutic element of claim 1 wherein said elongate member has a durometer in the range of about 20 to about 40.

28. The therapeutic element of claim 1 wherein said elongate member has a durometer in the range of about 20 to about 80.

29. A therapeutic element comprising:

an elongate member made of a bio-absorbable polymeric material;

radioactive seed elements; wherein

said radioactive seed elements are secured along the elongate member by molding said seed elements directly into the bio-absorbable polymeric material; and

said elongate member is axially rigid and radially flexible.

30. The therapeutic element of claim 29 , wherein

said radioactive seed elements are secured at desired intervals along the elongate member.

31. The therapeutic element of claim 29 , wherein each of said desired intervals is independently set.

32. The therapeutic implant of claim 31 , wherein said desired intervals are set by a pre-operative diagnosis plan of a patient.

33. The therapeutic implant of claim 29 , wherein the radioactive seed elements are secured along the elongate member without the use of pre-fabricated spacers.

34. The therapeutic implant of claim 29 , wherein said therapeutic implant is fashioned by compression molding techniques.

35. The therapeutic element of claim 29 wherein the polymeric material is a polymer.

36. The therapeutic element of claim 29 wherein the polymeric material is a co-polymer.

37. The therapeutic element of claim 29 wherein the polymeric material is a natural bio-compatible material.

38. The therapeutic element of claim 29 wherein the polymeric material is a synthetic bio-compatible material.

39. The therapeutic element of claim 29 wherein the polymeric material is a natural bio-absorbable material.

40. The therapeutic element of claim 29 wherein the polymeric material is a synthetic bio-absorbable material.

41. The therapeutic element of claim 29 wherein the elongated member has alternating segments of polymeric material and seed elements.

42. The therapeutic element of claim 29 wherein the elongated member has a substantially constant diameter.

43. The therapeutic element of claim 29 wherein the elongated member has a diameter substantially similar to the diameter of the radioactive seed elements.

44. The therapeutic element set forth in claim 29 wherein said elongate member is sufficiently rigid axially to prevent jamming or collapsing while being pushed out of a needle.

45. The therapeutic element set forth in claim 29 wherein said elongate member has sufficient radial flexibility to maintain locational accuracy relative to a tumor target as said tumor target shrinks in size.

46. The therapeutic element set forth in claim 29 wherein the thickness of said elongate member around said radioactive seeds is sufficient to decrease normal tissue necrosis from a high local dose of radiation.

47. The therapeutic element set forth in claim 29 wherein said polymeric material is impregnated with a hormone.

48. The therapeutic element set forth in claim 29 wherein said polymeric material is impregnated with a drug.

49. The therapeutic element set forth in claim 29 wherein said radioactive seed elements are positioned at various intervals along the length of said elongate member.

50. The therapeutic element set forth in claim 29 wherein said radioactive seed elements are impregnated with a hormone.

51. The therapeutic element set forth in claim 29 wherein said radioactive seed elements are impregnated with a drug.

52. The therapeutic element set forth in claim 29 wherein said radioactive seeds contain a compound or element that emits photonic radiation having a low energy and a short half-life.

53. The therapeutic element set forth in claim 29 wherein said radioactive seeds contain an isotope consisting of the group iodine 125, palladium 103, iridium 192, cesium 131, gold 198 yttrium 90 and phosphorus 32.

54. The therapeutic element set forth in claim 29 wherein said polymeric material is absorbed by living tissue within about 70 to 120 days after implant.

55. The therapeutic element set forth in claim 29 wherein said polymeric material is absorbed by living tissue at substantially the same time as the half-life of the radioactive seed elements are reached.

56. The therapeutic element set forth in claim 29 wherein said polymeric material is selected from the group consisting of polymers and copolymers of glycolide, lactide and polydiaxanone.

57. The therapeutic element set forth in claim 29 wherein said elongate member is echogenic.

58. The therapeutic element set forth in claim 29 wherein said elongate member has air bubbles dispensed within.

59. The therapeutic element of claim 29 wherein said elongate member has a durometer in the range of about 20 to about 40.

60. The therapeutic element of claim 29 wherein said elongate member has a durometer in the range of about 20 to about 80.

61. The therapeutic element of claim 29 wherein said polymeric material is moldable during manufacture of the therapeutic element.

62. The therapeutic element of claim 29 wherein the therapeutic element does not comprise spacers.

63. The therapeutic element of claim 29 wherein the radioactive seed elements are secured along the elongate member without spacers.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2016
From: ECKERT & ZIEGLER BEBIG S.A.
To: THERAGENICS CORPORATION
Reel/Frame 037475/0823 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE TOTAL ATTACHMENTS TO INCLUDE SCHEDULE A. DOCUMENT ID# 502678702. PREVIOUSLY RECORDED ON REEL 032145 FRAME 0713. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT ASSIGNMENT AGREEMENT.. Recorded Feb 12, 2014
From: BIOCOMPATIBLES UK, LTD.
To: ECKERT & ZIEGLER BEBIG S.A.
Reel/Frame 032435/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2014
From: BIOCOMPATIBLES UK, LTD.
To: ECKERT & ZIEGLER BEBIG S.A.
Reel/Frame 032145/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2009
From: WORLD WIDE MEDICAL OF FLORIDA, LLC
To: BIOCOMPATIBLES UK LIMITED
Reel/Frame 022960/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2009
From: IDEAMATRIX, INC.
To: WORLD WIDE MEDICAL OF FLORIDA, LLC
Reel/Frame 022960/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2008
From: WORLD WIDE MEDICAL TECHNOLOGIES, LLC
To: BIOCOMPATIBLES UK LIMITED
Reel/Frame 021354/0292 →